Adapting to change

sustaining care in a new world - Seite 3

Grifols                      

Precision BioLogic

BioMarin Pharmaceutical Inc.   

Kedrion                     

Sanofi Genzyme

Biotest                                       

LFB S.A                    

Sobi

CSL Behring                             

Novo Nordisk           

Spark Therapeutics

F. Hoffman-La Roche Ltd.         

Octapharma              

Takeda

GC Pharma                               

Pfizer                       

uniQure

About hemophilia and other bleeding disorders

Hemophilia, von Willebrand disease, inherited platelet disorders, and other factor deficiencies are lifelong bleeding disorders that prevent blood from clotting properly. People with bleeding disorders do not have enough of a particular clotting factor, a protein in blood that controls bleeding, or else it does not work properly. The severity of a person's bleeding disorder usually depends on the amount of clotting factor that is missing or not functioning. People with hemophilia can experience uncontrolled bleeding that can result from a seemingly minor injury. Bleeding into joints and muscles causes severe pain and disability while bleeding into major organs, such as the brain, can cause death.

About the World Federation of Hemophilia

For over 50 years, the World Federation of Hemophilia (WFH)—an international not-for-profit organization—has worked to improve the lives of people with hemophilia and other inherited bleeding disorders. Established in 1963, it is a global network of patient organizations in 140 countries and has official recognition from the World Health Organization. To find out more about the WFH, please visit  www.wfh.org.

Media contact: Neha Suchak, Director, Marketing & Communications, [e-mail], [phone], #2857, www.wfh.org

Photo - https://mma.prnewswire.com/media/1489594/World_Federation_of_Hemophilia_Adapting_to_change__sustaining_ca.jpg